Clinical trial reforms announced by the MHRA and Health Research Authority on 27 April 2026 will introduce faster routes for some studies from 28 April, including a system for lower risk trials and quicker approval of eligible modifications. The announcement also promises mandatory registration and publication of summary results. The microscope has welcomed the progress, provided nobody asks it to complete another form confirming that it has welcomed the progress.
The reforms are intended to make it easier to begin first in human trials, start lower risk studies and use evidence from overseas research and computer modelling where it meets UK standards. That is a serious attempt to remove avoidable delay without removing the safety checks that make a clinical trial different from waving a new medicine at a volunteer and hoping the clipboard looks confident.
The announcement says the combined MHRA and HRA review now takes an average of 41 days, while set up times for studies going through combined review have fallen from 169 days to 122. The government target was 150 days, so the figures have achieved the rare administrative miracle of arriving early and immediately being invited to explain themselves in triplicate.
The most entertainingly bureaucratic change is Route B. During its pilot, eligible applications for certain substantial modifications were processed in an average of seven calendar days. From 28 April, the route becomes part of the legal framework. Eligible modifications will be automatically approved unless concerns are raised within 14 calendar days and a full assessment is required.
This is not quite a clinical express checkout. Safety concerns remain central, and the route applies only to modifications that do not introduce new safety concerns. The fast lane therefore has a barrier, a ticket system and someone trained to ask whether the trolley contains anything more dangerous than another meeting.
The promise of greater transparency matters just as much. Registration and publication of summary results will become legal requirements, giving patients and researchers a clearer account of what trials exist and what they found. The microscope calls this excellent news, although the filing cabinet has already requested a six month consultation on whether the results are allowed to be legible.
Britain’s clinical trial system has not become a magic wand. It has become a little less like a locked cupboard labelled urgent and a little more like a route with signs. The microscope is delighted. It has finally reached the fast lane, only to discover that the fast lane is moving at speed while a form asks whether it has permission to move at speed.
Source: GOV.UK.
